Vivo Capital’s Regulus Therapeutics RGLS Stock Holding History

Vivo Capital’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,696,426	Closed	-$4.72M	–	45
2025 Q1	$4.72M	Sell	2,696,426 -2,303,574	-46%	-$3.04M	0.62%	32
2024 Q4	$7.9M	Hold	5,000,000	–	–	0.89%	28
2024 Q3	$7.85M	Hold	5,000,000	–	–	0.65%	26
2024 Q2	$8.93M	Hold	5,000,000	–	–	0.82%	24
2024 Q1	$14.4M	Buy	+5,000,000	New	+$8.15M	1.13%	21

Other funds holding RGLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vivo Capital's RGLS Position: Q2 2025 in Review

Vivo Capital sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 2,696,426 shares — an estimated $4.72M sold.

Vivo Capital first reported a position in RGLS in Q1 2024 and held it in 5 quarters. The position peaked at $14.4M in Q1 2024. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

Vivo Capital reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
Vivo Capital sold 2,696,426 Regulus Therapeutics shares in Q2 2025, an estimated $4.72M.
Vivo Capital first reported a position in Regulus Therapeutics in Q1 2024 and held it in 5 quarters.
Vivo Capital's Regulus Therapeutics position peaked at $14.4M in Q1 2024.
0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Vivo Capital's 13F filing for Q2 2025, filed 14 Aug 2025.